STAT+: Pharmalittle: Biogen ALS drug trial yields mixed signals; Novartis makes U.S. growth its top priority
Hello, everyone, and how are you today? A dank cloudy cover greeted us this morning,…
Category: STAT+
Bayer’s venture arm ramps up, seeking to invest $1.3 billion
Over the last six years, a venture capital team run out of pharmaceutical giant Bayer…
STAT+: Envision Healthcare teeters on the brink of bankruptcy
Envision Healthcare, the large chain of outpatient surgery centers and physician staffing services for hospitals,…
STAT+: Pharmalittle: FDA scolds Catalent over quality control at plant making Covid shots; Novartis will ask SCOTUS to protect a key patent
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Researchers show they can quickly turn CAR-T cells on and off, raising hopes for safer cancer treatments
Researchers reported Wednesday that they could quickly and reliably turn CAR-T cells on and off…
STAT+: Pharmalittle: Haleon argues it’s not liable for any Zantac claims; FDA steps up surprise inspections in India
Top of the morning to you, and a fine one it is. Crystal clear blue…
STAT+: New CRISPR startup, drawing big-name backers, seeks to fix diseases caused by large DNA errors
A new CRISPR startup — backed by some big names in venture capital — is…
STAT+: Minimal compliance, or meaningful change? Epic faces a crossroads as new rules put pressure on health data sharing
In the business of selling record-keeping software to hospitals, Epic Systems is breaking away from…
STAT+: Ruling against DOJ allows UnitedHealth bid for Change Healthcare to proceed
A federal judge on Monday shot down the U.S. Justice Department’s legal challenge to UnitedHealth…
STAT+: Pfizer accused of running a fellowship program that discriminates on racial grounds
In a move reflecting simmering controversy over diversity and equity, Pfizer has been accused of…
STAT+: Pharmalittle: Advances in treating the sickest Covid patients have stalled; Moderna aids WHO effort to develop mRNA coronavirus shots
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Patients for Affordable Drugs taps new leader
WASHINGTON — One of Washington’s most prominent drug pricing patient groups is tapping an advocate who…
STAT+: Have researchers hit a wall in the hunt for severe Covid drugs?
It seemed interminably slow then, what with all the haze and fear of fresh plague,…
STAT+: Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease
Intellia Therapeutics said Friday the first six patients to receive its CRISPR-based treatment for a…
STAT+: Humana appeases Wall Street with big projections of Medicare Advantage growth
Humana is targeting ambitious growth of its Medicare Advantage plans and primary care clinics over…
STAT+: Savvier buyers threaten mental health tech’s momentum
When the pandemic exposed long-festering problems around access to mental health care, many organizations started…
STAT+: Brazil dismisses antitrust complaint against Gilead over pricing for a hepatitis C drug
In a victory for Gilead Sciences, Brazilian antitrust authorities dismissed a complaint filed by several…
STAT+: Pharmalittle: Swiss authorities probe Novartis over patent used to block rivals; Medicare underserves older Americans with opioid use disorder
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Swiss authorities raid Novartis offices seeking info on patents used to block rivals
The Swiss Competition Commission has begun an investigation into Novartis over the possible unlawful use…
STAT+: Pharmalittle: Pharma pursues the ‘dream’ of online prescribing; EC chief under fire over Pfizer vaccine contract
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
.jpg)
STAT+: Medical pioneers team up to launch new cell therapy biotech
Medical pioneers Carl June, Bruce Levine, and Drew Weissman have teamed up to launch a…
STAT+: ‘This is pharma’s dream’: How drugmakers are turning telehealth into a marketing gold mine
A familiar refrain echoes through drug ads in the United States. It’s heard at the…
STAT+: Pharmalittle: Biden picks biotech exec to lead new biomedical research agency; FDA to hold meeting for OTC birth control pill
Hello, everyone, and how are you today? The skies over the Pharmalot campus remain gloomy…
STAT+: Akero treatment for NASH reduces liver scarring, achieves goals of mid-stage study
Akero Therapeutics said Tuesday that an experimental medicine improved liver scarring at twice the rate…
STAT+: Data likely support approval of Amgen’s KRAS-targeted drug, but still come with disappointments
Clinical trial results reported Monday by Amgen may be enough to confirm the U.S. approval…
STAT+: Pretzel Therapeutics, eyeing diseases caused by broken mitochondria, launches with $72.5 million
In the life sciences industry, where company names derived from “biology” or “genetics” are a…
STAT+: Pharmalittle: FDA approves new type of psoriasis drug; U.S. starts late-stage trial to test an antiviral against monkeypox
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Experts urge Medicare to overhaul secretive panel that helps determine doctors’ pay
A heavyweight group of former Medicare officials and payment experts are calling on the federal…
STAT+: Boston’s most valuable biotech? It’s not who you might expect
The brightest star in Boston’s rapidly growing biotech scene isn’t a flashy new player, but…
STAT+: Cancer treatment devised in the 1980s has proven effective (again). Will it finally get approval?
Eight years ago, a Dutch oncologist, John Haanen, set out to change melanoma treatment by…
.jpg)
STAT+: USDA starts cracking down on companies that ship animals without timely inspections
Earlier this year, a leading animal rights group asked U.S. authorities to investigate medical research…
STAT+: J&J wins a partial appeal against the U.K.’s cost-effectiveness watchdog over ‘unfair’ review
In an unusual turn of events, an appeals panel ruled that the U.K.’s cost effectiveness…
STAT+: Home Depot, other employers appeal Blue Cross Blue Shield antitrust settlement
Home improvement retailer Home Depot and two other, smaller employers are appealing a recent $2.67…
STAT+: FDA funding negotiations heat up ahead of September deadline
WASHINGTON — Negotiations are intensifying over massive, multibillion-dollar legislation to fund the Food and Drug…
STAT+: Alphabet spinout Verily raises $1 billion as it looks to harness health data
Alphabet’s life sciences offshoot Verily said Friday that it has raised $1 billion to fuel…
STAT+: Pharmalittle: FDA approves a new wrinkle drug; running remote clinical trials can save pharma money
And so, another working week will soon draw to a close. Not a moment too…
STAT+: What disclosure? Clinical trials run in Canada fail to take basic steps toward transparency
Amid ongoing controversy over clinical trial transparency, a new analysis found that just 3% of…
STAT+: Even before Covid-19, remote trials saved money. Will pharma now rely on them more than ever?
Running clinical trials remotely or virtually can provide substantial financial savings for pharmaceutical companies, according…
STAT+: Pharmalittle: FDA advisers recommend approval of controversial ALS drug; judge rules against coverage of HIV prevention drugs
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Advocates wanted Juul’s big settlement to overhaul the e-cigarette landscape. It likely won’t, experts warn
WASHINGTON – On Tuesday, a group of more than 30 attorneys general announced they had…
STAT+: Data show strong results for Alnylam therapy for heart disease, but magnitude of benefit will stir debate
Detailed data from a successful heart disease study show a therapy developed by Alnylam Pharmaceuticals…
STAT+: In reversal, FDA advisers vote a second time to support approval of Amylyx’s drug for ALS
At the end of an unusual and dramatic meeting on Wednesday, an independent panel of…
STAT+: Gilead drug prolongs survival of women with common form of breast cancer
Gilead Sciences said Wednesday that its cancer drug Trodelvy prolonged the survival of women with…
Relay Therapeutics drug shows promise in early trial
A daily dose of Relay Therapeutics’ experimental drug for cholangiocarcinoma, a rare cancer of the…
STAT+: UnitedHealth signs a deal with Walmart for a new Medicare Advantage plan
UnitedHealth Group is poised to widen its lead in the Medicare Advantage market through a…
STAT+: Pharmalittle: FDA holds rare second meeting over an ALS drug; U.S. to expand distribution for monkeypox vaccine
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy
Good Therapeutics, a private company that raised just $30 million in venture financing since its…
STAT+: Tobacco giant Philip Morris is investing billions in health care. Critics say it’s peddling cures for its own poison
A new health care company was quietly incorporated last month, with plans to leverage cutting-edge…
STAT+: Pharma donations to patient charities may violate the ‘spirit’ of anti-kickback laws
There is a federal law that prohibits drug companies from directly covering out-of-pocket spending by…